WaveMan
WaveMan · Company
BVS · Bioventus Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

BVS Bioventus (BVS) Insider Trading, Ownership & Congress Trades

Medical Devices · Surgical & medical instruments & apparatus · CIK 0001665988
Quote by TradingView
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
102
13F, latest reported quarter
Conversions, 180 days
10
Codes C/M, not in net · $0 priced

Bioventus insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

No insider purchases or sales are on record for Bioventus Inc. in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
McMurry-Heath Michelle
Director
SELL
2026-03-13 SECtraded 2026-03-11
12,000
$105.5K
+62.6%
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on Nov 7, 2025.
  • The trade is 26.7% of the 44,997 shares held after it.
  • No other insider sold within 30 days.
  • 102 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director McMurry-Heath Michelle sold about $105.5K of BVS on Mar 11, 2026; 102 funds added in the latest 13F quarter.
NOHRA GUY P
Director
SELL
2025-12-08 SECtraded 2025-12-04
10,000
$75.7K
+100.6%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 8.6% of the 116,610 shares held after it.
  • 1 other insider sold within 30 days.
  • 102 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director NOHRA GUY P sold about $75.7K of BVS on Dec 4, 2025; 1 other insider sold within 30 days and 102 funds added in the latest 13F quarter.
McMurry-Heath Michelle
Director
SELL
2025-11-10 SECtraded 2025-11-07
17,701
$131.3K
+87.3%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 31.1% of the 56,997 shares held after it.
  • 1 other insider sold within 30 days.
  • 102 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director McMurry-Heath Michelle sold about $131.3K of BVS on Nov 7, 2025; 1 other insider sold within 30 days and 102 funds added in the latest 13F quarter.
Singleton Mark Leonard
SVP & CFO
SELL
2025-04-15 SECtraded 2025-04-11
3,875
$29.3K
+85.3%
Context
  • 8 earlier Form 4 trades (code P or S) here by this insider (8 sales), the last on Mar 24, 2025.
  • The trade is 2.7% of the 141,088 shares held after it.
  • 2 other insiders sold within 30 days.
  • 102 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: SVP & CFO Singleton Mark Leonard sold about $29.3K of BVS on Apr 11, 2025; 2 other insiders sold within 30 days and 102 funds added in the latest 13F quarter.
D'Adamio Anthony
SVP & General Counsel
SELL
2025-04-15 SECtraded 2025-04-11
2,958
$22.4K
+85.3%
Context
  • 10 earlier Form 4 trades (code P or S) here by this insider (10 sales), the last on Mar 17, 2025.
  • The trade is 2.3% of the 131,416 shares held after it.
  • 2 other insiders sold within 30 days.
  • 102 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: SVP & General Counsel D'Adamio Anthony sold about $22.4K of BVS on Apr 11, 2025; 2 other insiders sold within 30 days and 102 funds added in the latest 13F quarter.
67 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 62 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
102 funds bought in last quarter
more than 64% of Medical Devices
Revenue
-0.9% year over year
below 79% of Medical Devices
Margin
4.0% net margin
more than 72% of Medical Devices
Buybacks
no share repurchases reported
Short interest
9.3% of the float short (float per yahoo 2026-10-27) · 8.9 days to cover · settled 2026-10-15
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch BVS

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+107.2%12M
-6%+36%+77%+119%2025-102025-122026-022026-042026-062026-082026-10 2025-11-07 · McMurry-Heath Michelle sold $131.3K2026-03-11 · McMurry-Heath Michelle sold $105.5K2025-12-04 · NOHRA GUY P sold $75.7K
Insider sell
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns BVS: institutional holders (13F)

13F holdings, latest reported quarter
Essex Woodlands Management, Inc.
13,021,324 sh
$122.9M
Nantahala Capital Management, LLC
12,000,558 sh
$113.3M
Juniper Investment Company, LLC
6,939,357 sh
$65.5M
BlackRock, Inc.
3,435,914 sh
$32.4M
ROYCE & ASSOCIATES LP
1,833,212 sh
$17.3M

Congress trades in BVS

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

BVS planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.

BVS mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Knights of Columbus Small Cap Equity Fund
$2.7M position · as of 2026-07-31
1.3%
Inspire Fidelis Multi Factor ETF
$1.7M position · as of 2026-05-31
0.9%
WesMark Small Company Fund
$1.3M position · as of 2026-06-30
0.7%
State Street(R) SPDR(R) S&P(R) Health Care Equipment ETF
$978.6K position · as of 2026-06-30
0.6%
Royce Small-Cap Opportunity Fund
$8.1M position · as of 2026-06-30
0.6%
NORTH SQUARE KENNEDY MICROCAP FUND
$162.4K position · as of 2026-05-31
0.5%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows 102 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
PENBLFSMTDSIBNWRBYISRGTXGDXCMEWTMDXOMIRMD

BVS financials

Revenue growth
-0.9%
XBRL, annual
Net margin
4.0%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$581.8M
four quarters, 2025-06-29 to 2026-06-27
Net margin, TTM
+9.4%
net income over revenue, 2025-06-29 to 2026-06-27
Free cash flow, TTM
$94.3M
operating cash flow minus capex, 2025-06-29 to 2026-06-27
Debt to equity
1.09x
long-term 2026-06-27 plus current 2026-06-27; equity 2026-06-27
Cash flow to debt
0.39x
TTM operating cash flow over long-term 2026-06-27 plus current 2026-06-27
Return on equity
+28.0%
TTM net income over average of 2025-06-28 and 2026-06-27
Return on assets
+7.9%
TTM net income over average of 2025-06-28 and 2026-06-27
Return on invested capital
n/a
effective tax rate -59%, not meaningful
Return on capital employed
+11.2%
operating income (EBIT proxy) over average of 2025-06-28 and 2026-06-27 minus current liabilities
P/E, trailing
18.73x
close 2026-10-27 over four quarters of diluted EPS, 2025-06-29 to 2026-06-27
Enterprise value
n/a
no share count filed
FCF yield
n/a
no share count filed
PEG, trailing
n/a
prior-year trailing EPS was a loss, growth undefined
Price as of 2026-10-27. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$568.1M$573.3M$512.3M$512.1M
Gross profit$388.2M$388.2M$328.2M$331.1M
Operating income$54.0M-$15.2M-$81.7M-$167.2M
Net income$22.7M-$36.1M-$156.2M-$158.7M
EPS (diluted)0.33-0.56-2.49-2.59
Operating cash flow$74.7M$38.8M$15.3M-$13.5M
Cash$51.2M$41.6M$37.0M$30.2M
Long-term debt$279.0M$308.3M$367.0M$385.0M
SEC XBRL, fiscal years, as known on 2026-10-28

BVS Stock Sonar score 5/7 axes

Find similar shapesCompare

BVS ranks highest on profitability (87th percentile) and institutional and government (64th), and lowest on growth (21st), among Medical Devices peers.

ProfitHealthGrowthInstitutionsRisk
Profitability
87
Inputs
  • Return on equity+28.0% · 93 pct, sector of 183
  • Return on assets+7.9% · 83 pct, sector of 214
  • Return on invested capitaleffective tax rate -59%, not meaningful
  • Return on capital employed+11.2% · 84 pct, sector of 188
Financial health
48
Inputs
  • Debt to equity1.09x · 15 pct, sector of 159
  • Cash flow to debt0.39x · 80 pct, sector of 150
Growth
21
Inputs
  • Revenue growth, YoY-0.9% · 21 pct, sector of 219
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Institutional and government
64
Inputs
  • Funds adding, latest quarter102 · 64 pct, sector of 191
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
60
Inputs
  • Short interest, % of float+9.3% · 25 pct, sector of 241
  • Recalls per $1B revenue, 3y0.00 per $1B · 100 pct, sector of 116
  • EPA cases per $1B revenue, 5ynot measured for this sector, almost no peer has an event
  • New text in Risk Factors, latest 10-K+9.6% · 55 pct, sector of 198
2 not measured: Insider conviction, US patents
  • Insider conviction needs 1 of 2 inputs, 0 present: no Form 4 purchase or sale (code P or S) in 180 days; no insider trades in 180 days
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies